DNA Vaccine Safely Lowers Toxic Amyloid and Tau Aggregates in Brains of Mice with Alzheimer’s, Study Says

DNA Vaccine Safely Lowers Toxic Amyloid and Tau Aggregates in Brains of Mice with Alzheimer’s, Study Says
Use of an active DNA vaccine in mice with hallmarks of Alzheimer’s disease significantly lowered the toxic accumulation of amyloid plaques and tau without triggering severe brain swelling — a damaging complication seen in earlier antibody treatments. These results may pave the way to test this DNA vaccine in clinical trials, researchers said. The study, "Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology," was published Alzheimer's Research & Therapy. Immunotherapy – the treatment of disease by utilizing the immune system – has potential as an Alzheimer's treatment. However, current assessments of amyloid-beta (Aβ) immunotherapy in preventing this disease in several completed and ongoing trials show inconsistent responses. Notably, the first active anti-Aβ peptide clinical trial of a DNA amyloid-beta peptide 1–42 (Aβ42) vaccine in Alzheimer's patients led to encephalitis – inflammation of the brain that causes mild to life-threatening symptoms. Of note, Aβ42 is one of the forms that amyloid-beta peptide fragments — those that accumulate in a patient's brain — can assume. These are mainly found in amyloid plaques and correlate with disease status. To avoid complications like autoimmune inflammation and encephalitis, many ongoing clinical trials are now utilizing passive vaccination with mouse or human antibodies against amyloid-beta protein. Passive vaccination is the direct application of antibodies, ins
Subscribe or to access all post and page content.

One comment

  1. sam schwarm says:

    I have read a number of scientific papers indicating a correlation between human exposure to the cyanotoxin BMAA and alzheimers.What is the consensus opinion on this issue among medical professionals?

Leave a Comment

Your email address will not be published. Required fields are marked *